Irbesartan HCTZ MLabs 150/12.5 irbesartan 150 mg and hydrochlorothiazide 12.5 mg tablets blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

irbesartan, Quantity: 150 mg; hydrochlorothiazide, Quantity: 12.5 mg

Disponible depuis:

Micro Labs Pty Ltd

DCI (Dénomination commune internationale):

Hydrochlorothiazide,Irbesartan

forme pharmaceutique:

Tablet, film coated

Composition:

Excipient Ingredients: polysorbate 80; sodium starch glycollate type B; colloidal anhydrous silica; mannitol; hypromellose; povidone; magnesium stearate; titanium dioxide; iron oxide yellow; iron oxide red; Carnauba Wax; macrogol 3350

Mode d'administration:

Oral

Unités en paquet:

30 (3x10 in carton)

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

Indicated for the treatment of hypertension. Treatment should not be initiated with this fixed-dose combination.

Descriptif du produit:

Visual Identification: Peach coloured, capsule shaped, biconvex, film-coated tablets, approx. 14 mm long and 7 mm wide, debossed with 'IH' on one face and plain on other face.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Licence status A

Date de l'autorisation:

2017-03-14

Résumé des caractéristiques du produit

1
AUSTRALIAN PRODUCT INFORMATION
IRBESARTAN HCTZ MLABS 150/12.5 MG, 300/12.5 MG, 300/25 MG
(IRBESARTAN/HYDROCHLOROTHIAZIDE) TABLETS
1 NAME OF THE MEDICINE
Irbesartan/Hydrochlorothiazide
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Irbesartan HCTZ MLabs 150/12.5 mg tablets contain 150mg of irbesartan
and 12.5mg of
hydrochlorothiazide.
Irbesartan HCTZ MLabs 300/12.5 mg tablets contain 300mg of irbesartan
and 12.5mg of
hydrochlorothiazide.
Irbesartan HCTZ MLabs 300/25 mg tablets contain 300mg of irbesartan
and 25mg of
hydrochlorothiazide
For the full list of excipients, see Section 6.1 List of excipients.
3 PHARMACEUTICAL FORM
IRBESARTAN HCTZ MLABS 150/12.5MG FILM-COATED TABLETS:
Film-coated tablets containing 150mg of irbesartan and 12.5mg of
hydrochlorothiazide. Peach
coloured, capsule shaped, biconvex, film-coated tablets, approximately
14 mm long and 7 mm
wide, debossed with ‘IH’ on one face and plain on other face.
IRBESARTAN HCTZ MLABS 300/12.5 MG FILM-COATED TABLETS:
Film-coated tablets containing 300mg of irbesartan and 12.5mg of
hydrochlorothiazide. Peach
coloured, capsule shaped, biconvex, film-coated tablets, approximately
18 mm long and 9 mm
wide debossed with ‘IH2’ on one face and plain on other face.
IRBESARTAN HCTZ MLABS 300/25 MG FILM-COATED TABLETS:
Film-coated tablets containing 300mg of irbesartan and 25mg of
hydrochlorothiazide. Brick red
coloured, capsule shaped, biconvex, film-coated tablets, approximately
18 mm long and 9 mm
wide, debossed with ‘IH1’ on one face and plain on other face.
2
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Irbesartan HCTZ MLabs is indicated for the treatment of hypertension.
Treatment should not be
initiated with this fixed-dose combination.
4.2 DOSE AND METHOD OF ADMINISTRATION
Irbesartan HCTZ MLabs should not be initiated as first-line therapy.
The daily dose can be
administered with or without food.
REPLACEMENT THERAPY
The combination may be substituted for the titrated components at the
same dose level.
DOSE TITRATION BY CLINICAL EFFECT
When clini